Hormontherapie im Klimakterium

Kernaussagen

Die Hormontherapie (HT) in der Peri- und Postmenopause ist eine häufig indizierte Pharmakotherapie. Die HT sollte nur bei einer eindeutigen Indikation im Sinne der vorliegenden Leitlinienempfehlungen eingesetzt werden. Bei Beginn und im Intervall sollte mit der Patientin eine Nutzen-Risiken-Analyse der HT durchgeführt werden. Für die meisten Frauen ist die kurzzeitige Behandlung der vasomotorischen Beschwerden oder der Vaginalatrophie mit Östrogenen eine gute Option. Längerfristige Therapien können jedoch bei behandlungsbedürftigen Symptomen erforderlich sein. Verschiedene Präparate und Applikationsformen stehen zur Verfügung. Eine weitere Krankheitsprävention ist mit Östrogenen als First-Line-Therapie nicht möglich oder empfehlenswert.

• Literatur

• 1 New Zealand Guidelines Group. The appropriate prescribing of hormone replacement therapy. Best practice evidence-based guideline. Manatū Hauora, Māori, Neuseeland: New Zealand Guidelines Group; 2001
• 2 Arzneimittelkommission der Deutschen Ärzteschaft. Hormontherapie im Klimakterium. http://www.akdae.de/Arzneimitteltherapie/TE/A-Z/PDF/Hormontherapie.pdf
• 3 Maclennan AH, Broadbent JL, Lester S et al. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004; (4) CD002978
• 4 North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society. Menopause 2007; 14: 168-182
• 5 Vesco KK, Haney EM, Humphrey L et al. Influence of menopause on mood: a systematic review of cohort studies. Climacteric 2007; 10: 448-465
• 6 Eberhardt S, Kulp W, von der Schulenburg JM et al. Hormones for therapy of climacteric afflictions. GMS health technology assessment 2007; 3: Doc03
• 7 Utian WH, Archer DF, Bachmann GA et al. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008; 15: 584-602
• 8 Perrotta C, Aznar M, Mejia R et al. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev 2008; (2) CD005131
• 9 Deutsche Gesellschaft für Gynäkologie und Geburtshilfe. S3-Leitlinie „Hormontherapie in der Peri- und Postmenopause“. http://www.awmf.org/leitlinien/detail/ll/015-062.html
• 10 LaCroix AZ, Chlebowski RT, Manson JE et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. J Am Med Assoc 2011; 305: 1305-1314
• 11 Anderson GL, Chlebowski RT, Aragaki AK et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Womenʼs Health Initiative randomised placebo-controlled trial. Lancet Oncol 2012; 13: 476-486
• 12 Moehrer B, Hextall A, Jackson S. Oestrogens for urinary incontinence in women. Cochrane Database Syst Rev 2003; (2) CD001405
• 13 Grady D, Brown JS, Vittinghoff E et al. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol 2001; 97: 116-120
• 14 Barnabei VM, Cochrane BB, Aragaki AK et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Womenʼs Health Initiative. Obstet Gynecol 2005; 105: 1063-1073
• 15 Ortmann O. Hormontherapie in der Peri- und Postmenopause. Frauenarzt 2009; 50: 840-851
• 16 The North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010; 17: 242-255
• 17 Dannecker C, Friese K, Stief C et al. Urinary incontinence in women: part 1 of a series of articles on incontinence. Dtsch Arzteblatt Int 2010; 107: 420-426
• 18 Ortmann O, Dören M, Windler E. Hormone therapy in perimenopause and postmenopause (HT): Interdisciplinary S3 Guideline, Association of the Scientific Medical Societies in Germany AWMF 015/062-short version. Arch Gynecol Obstet 2011; 284: 343-355
• 19 Deutsche Gesellschaft für Osteologie e.V. (DGO). S3 Leitlinie „Prophylaxe, Diagnostik und Therapie der Osteoporose bei Frauen ab der Menopause, bei Männern ab dem 60. Lebensjahr“. http://www.awmf.org/uploads/tx_szleitlinien/034-003_S3_Prophylaxe__Diagnostik_und_Therapie_der_Osteoporose_bei_Erwachsenen_lang_10-2009_12-2012.pdf
• 20 Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. J Am Med Assoc 2001; 285: 2891-2897
• 21 Wells G, Tugwell P, Shea B et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002; 23: 529-539
• 22 Farquhar CM, Marjoribanks J, Lethaby A et al. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2005; (3) CD004143
• 23 MacLean C, Newberry S, Maglione M et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008; 148: 197-213
• 24 Beral V, Reeves G, Bull D et al. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 2011; 103: 296-305
• 25 The North American Menopause Society. The 2012 hormone therapy position statement of The North American Menopause Society. Menopause 2012; 19: 257-271
• 26 Zhou B, Sun Q, Cong R et al. Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecol Oncol 2008; 108: 641-651
• 27 Morch LS, Lokkegaard E, Andreasen AH et al. Hormone therapy and ovarian cancer. J Am Med Assoc 2009; 302: 298-305
• 28 Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999; 106: 574-582
• 29 Tsilidis KK, Allen NE, Key TJ et al. Menopausal hormone therapy and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2011; 128: 1881-1889
• 30 Freeman EW, Sammel MD, Lin H et al. Duration of menopausal hot flushes and associated risk factors. Obstet Gynecol 2011; 117: 1095-1104
• 31 Grady D, Gebretsadik T, Kerlikowske K et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995; 85: 304-313
• 32 World Health Organization. Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy. IARC monographs on the evaluation of carcinogenic risks to humans/World Health Organization, International Agency for Research on Cancer 2007; 91: 1-528
• 33 Nelson HD, Vesco KK, Haney E et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. J Am Med Assoc 2006; 295: 2057-2071
• 34 The North American Menopause Society. Menopause Practice: A Clinicianʼs Guide. 4th ed. Mayfield Heights, OH, USA: The North American Menopause Society; 2010